Friday, May 9, 2025 5/9/2025

Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone

Award Number: R01DE033583
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone - ABSTRACT Sjögren's disease is an autoimmune condition characterized by chronic inflammation and diminished secretory function of the salivary glands. Although extensive investigation has been done to understand it, causes of and effective treatments for the disease are still unknown. Given the high degree of need and the limitations of current therapies, development of novel treatments to decrease inflammation and restore salivary gland secretory function is essential. Previous studies demonstrated that a treatment with aspirin-triggered RvD1 and dexamethasone (AT-RvD1/DEX) reverses Sjögren's disease-like features in NOD/ShiLtJ mice at disease onset but the utility of this treatment is currently limited because the minimum effective dosage has yet to be established. Specifically, although AT-RvD1 has no known side effects, its relatively high cost could limit affordability. More importantly, DEX has been demonstrated to have significant side effects that can be expected to impede long-term use. By determining AT-RvD1/DEX biodistribution using mathematical modeling and thus defining the optimal (i.e., minimum effective) treatment dose, it is possible to manage the issues presented by both drugs and in so doing produce a cost-effective and clinically safe treatment option to mitigate symptoms associated with Sjögren's disease. To that end, it is hypothesized that systemic delivery of AT-RvD1/DEX will restore salivary gland secretory function in Sjögren's disease. Aim 1 will reduce AT-RvD1/DEX doses to their minimum effective levels, while Aim 2 will explore mechanisms by which AT-RvD1/DEX treatment outcomes are achieved and Aim 3 will apply AT-RvD1/DEX treatment to humanized systems.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $501,231 )
2025	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Oral Diseases and Disorders Research	001	2	5/5/2025	NON-COMPETING CONTINUATION	$50,123
2025	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Oral Diseases and Disorders Research	000	2	12/10/2024	NON-COMPETING CONTINUATION	$451,108
														Subtotal = $501,231

Issue Date FY: 2024 ( Subtotal = $502,709 )
2024	2024	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Oral Diseases and Disorders Research	000	1	12/30/2023	NEW	$502,709
														Subtotal = $502,709

Grand Total All Awards = $1,003,940

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone

Award Number: R01DE033583

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer